The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
Alternatively, my colleague Richard Isaacson, with whom I have spoken to on the podcast (link below), characterizes AD based on clinical markers and attributes and then addresses the individual’s risk based on the markers that he sees. I wonder if this strategy is a more practical way to subtype AD.
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.